ATE528009T1 - Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten - Google Patents

Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten

Info

Publication number
ATE528009T1
ATE528009T1 AT07108593T AT07108593T ATE528009T1 AT E528009 T1 ATE528009 T1 AT E528009T1 AT 07108593 T AT07108593 T AT 07108593T AT 07108593 T AT07108593 T AT 07108593T AT E528009 T1 ATE528009 T1 AT E528009T1
Authority
AT
Austria
Prior art keywords
gum
xanthang
reepithelializing
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT07108593T
Other languages
English (en)
Inventor
Maria Mazzone
Grazia Paladino
Clara Marino
Ornella Peri
Vincenzo Enea
Original Assignee
Sifi Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sifi Spa filed Critical Sifi Spa
Application granted granted Critical
Publication of ATE528009T1 publication Critical patent/ATE528009T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/723—Xanthans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07108593T 2002-04-30 2002-04-30 Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten ATE528009T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02425274A EP1358883B8 (de) 2002-04-30 2002-04-30 Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
ATE528009T1 true ATE528009T1 (de) 2011-10-15

Family

ID=28799773

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07108593T ATE528009T1 (de) 2002-04-30 2002-04-30 Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten
AT02425274T ATE367165T1 (de) 2002-04-30 2002-04-30 Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02425274T ATE367165T1 (de) 2002-04-30 2002-04-30 Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen

Country Status (15)

Country Link
US (5) US8912164B2 (de)
EP (2) EP1358883B8 (de)
JP (2) JP4837912B2 (de)
CN (1) CN100502884C (de)
AT (2) ATE528009T1 (de)
AU (1) AU2003230224B2 (de)
BR (1) BR0304655A (de)
CA (2) CA2749172C (de)
DE (2) DE07108593T1 (de)
DK (1) DK1358883T3 (de)
ES (2) ES2304913T3 (de)
MX (1) MXPA04010668A (de)
PT (1) PT1358883E (de)
RU (1) RU2297230C2 (de)
WO (1) WO2003092706A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE528009T1 (de) * 2002-04-30 2011-10-15 Sifi Spa Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten
WO2003094937A1 (en) 2002-05-09 2003-11-20 Medigenes A pharmaceutical composition for treatment of wounds containing blood plasma or serum
KR101301839B1 (ko) * 2004-09-28 2013-08-29 센주 세이야꾸 가부시키가이샤 잔탄 검 및 아미노산을 함유하는 안과용 조성물
ITRM20050443A1 (it) * 2005-08-12 2007-02-13 Opocrin Spa Preparati oftalmici a base di polisaccaridi mucoadesivi con capacita' riepitelizzante della cornea.
US7323184B2 (en) 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
WO2007108541A1 (ja) 2006-03-23 2007-09-27 Senju Pharmaceutical Co., Ltd. キサンタンガムおよびブドウ糖を含有する眼科用組成物
EP2309980A1 (de) * 2008-07-08 2011-04-20 S.I.F.I. Societa' Industria Farmaceutica Italiana Ophthalmische zusammensetzungen zur behandlung von erkrankungen des hinteren augensegments
JP5620168B2 (ja) * 2010-06-30 2014-11-05 Ｄｓｐ五協フード＆ケミカル株式会社 キシログルカン−カチオン複合体及びそれを含有する安定化組成物
IT1404145B1 (it) * 2010-12-27 2013-11-15 Altergon Sa Composizioni di acido ialuronico stabilizzate verso l'azione di degradazione del calore o degli enzimi
JP5960720B2 (ja) 2011-11-24 2016-08-02 東洋精糖株式会社 角結膜保護剤または角結膜障害抑制剤
WO2016185935A1 (ja) * 2015-05-18 2016-11-24 柿原秀己 抗菌物質及び液状抗菌剤並びに液状抗菌剤の製造方法
CN108472351A (zh) * 2015-12-29 2018-08-31 英特维特国际股份有限公司 球虫病疫苗
CN106236704A (zh) * 2016-08-30 2016-12-21 上海昊海生物科技股份有限公司 一种兼具仿生和靶向功能的莫西沙星滴眼液及其制备方法
CN114245737A (zh) 2019-06-11 2022-03-25 司斐股份有限公司 微乳剂组合物
IT202000002296A1 (it) * 2020-02-06 2021-08-06 Sifi Spa Formulazioni topiche oftalmiche a base di xantano con ridotta posologia
IT202000015457A1 (it) * 2020-06-26 2021-12-26 Sifi Spa Composizione oftalmica e suo uso nel trattamento di patologie dell’occhio
MX2021003369A (es) * 2021-03-22 2022-09-23 Laboratorios Grin S A De C V Lágrima ocular triple.
IT202200000821A1 (it) * 2022-01-19 2023-07-19 Sifi Spa Formulazioni topiche oftalmiche a base di xantano con ridotta posologia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4370324A (en) 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
US4826872A (en) 1986-12-03 1989-05-02 Takeda Chemical Industries, Ltd. Pharmaceutical composition for treatment of cataract
JPH0723317B2 (ja) * 1988-03-17 1995-03-15 生化学工業株式会社 角膜上皮層障害症治療剤
JPH0651638B2 (ja) * 1989-02-13 1994-07-06 新技術事業団 角膜上皮創傷治療用点眼剤
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
IT1243435B (it) * 1990-10-05 1994-06-10 Altergon Sa Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti
US5804213A (en) * 1991-10-09 1998-09-08 Lectec Corporation Biologically active aqueous gel wound dressing
US6277365B1 (en) * 1997-09-18 2001-08-21 Bausch & Lomb Incorporated Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent
DE69909768T2 (de) * 1998-04-07 2004-06-17 Alcon Manufacturing Ltd., Fort Worth Xanthangummi enthaltende gelbildende ophthalmische zusammensetzungen
DE20022450U1 (de) * 1999-01-19 2002-01-17 Dr. Gerhard Mann Chem.-pharm. Fabrik GmbH, 13581 Berlin Künstliche Tränenflüssigkeit in Gelform
BR0017340A (pt) * 2000-08-23 2003-12-09 Phairson Medical Inc Tratamento de trauma e outras indicações
AU2002232437A1 (en) * 2000-12-20 2002-07-01 Alcon Universal Ltd. Ophthalmic lubricating solution adapted for use in lasik surgery
RU2190388C1 (ru) * 2001-06-09 2002-10-10 Высоков Виктор Игоревич Средство на основе масла чайного дерева (варианты)
ATE528009T1 (de) * 2002-04-30 2011-10-15 Sifi Spa Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten

Also Published As

Publication number Publication date
CA2484020A1 (en) 2003-11-13
US20050234011A1 (en) 2005-10-20
DE60221227D1 (de) 2007-08-30
AU2003230224B2 (en) 2008-07-17
ATE367165T1 (de) 2007-08-15
CA2749172C (en) 2013-04-09
CA2749172A1 (en) 2003-11-13
CN100502884C (zh) 2009-06-24
CN1649602A (zh) 2005-08-03
EP1913948A1 (de) 2008-04-23
US20080146530A1 (en) 2008-06-19
JP2005529906A (ja) 2005-10-06
WO2003092706A1 (en) 2003-11-13
DE60221227T2 (de) 2008-01-31
US20080139502A1 (en) 2008-06-12
JP4837912B2 (ja) 2011-12-14
AU2003230224A1 (en) 2003-11-17
MXPA04010668A (es) 2005-06-20
CA2484020C (en) 2011-10-25
BR0304655A (pt) 2004-07-20
EP1358883B1 (de) 2007-07-18
ES2290264T3 (es) 2008-02-16
EP1358883A1 (de) 2003-11-05
EP1358883B8 (de) 2007-10-03
JP2011102315A (ja) 2011-05-26
RU2004131550A (ru) 2005-06-10
DE07108593T1 (de) 2008-12-04
US20160166601A1 (en) 2016-06-16
PT1358883E (pt) 2007-10-01
DK1358883T3 (da) 2007-11-12
ES2304913T1 (es) 2008-11-01
RU2297230C2 (ru) 2007-04-20
US8912164B2 (en) 2014-12-16
US20080139522A1 (en) 2008-06-12
EP1913948B1 (de) 2011-10-12
JP5203472B2 (ja) 2013-06-05
ES2304913T3 (es) 2012-03-01

Similar Documents

Publication Publication Date Title
ATE528009T1 (de) Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten
ATE464880T1 (de) Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
EP2070509A3 (de) Die Verwendung von Myrica gale Öl
PE20080374A1 (es) Composiciones farmaceuticas de ropinirol
ATE179884T1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
DE60329994D1 (de) Selbstbräuner enthaltend wasserlösliche Vitamin B3-Komponente und Bräunungswirkstoff mit Alpha-Hydroxycarbonyl-Gruppierung
IS7820A (is) Samsetningar sem innihalda melatónín, musterisviðog bíótín
NO20041509L (no) Rengjoringspreparat.
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE60025503D1 (de) Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten
AR059113A1 (es) Composicion para administracion topica
DE60232271D1 (de) Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen
CA2529441A1 (en) Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas
DE60236025D1 (de) Pharmazeutische zusammensetzung enthaltend l-arginin
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
ATE417619T1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung
EA200702496A1 (ru) Местная композиция, содержащая желатин
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
TW200509941A (en) Pharmaceutical solution composition
UY27376A1 (es) Formulación de medicamento que contiene un antagonista de ltb4
IL153010A0 (en) 3,3-dimethylcyclohexane derivatives
HRPK20040924B3 (en) Preparation based on curcumae longae rhizomae roots
EA200701525A1 (ru) Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением
BR0314874A (pt) Composição de tiofeno anti-helmìntica e inseticidas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties